Left ventricular systolic function following alcohol septal ablation for symptomatic hypertrophic cardiomyopathy

Travis J Moss1, Mori J Krantz2, Matthew M Zipse1

  • 1Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Insights

Alcohol septal ablation (ASA) for hypertrophic cardiomyopathy (HC) preserves left ventricular (LV) systolic function in most patients. This treatment effectively reduces LV outflow tract obstruction and improves symptoms, with only mild LV dysfunction observed in a small minority.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Imaging

Background:

  • Alcohol septal ablation (ASA) is a treatment for symptomatic hypertrophic cardiomyopathy (HC) with left ventricular (LV) outflow tract (LVOT) obstruction.
  • ASA intentionally creates a myocardial infarct, raising concerns about potential long-term decline in LV systolic function.

Purpose of the Study:

  • To evaluate the longitudinal changes in LV systolic function and other echocardiographic parameters in patients undergoing ASA for symptomatic HC.

Main Methods:

  • A cohort of 145 consecutive patients with HC who underwent 167 ASA procedures between 2002 and 2011 were studied.
  • Echocardiographic follow-up, including LV ejection fraction (LVEF), mitral regurgitation, and LVOT gradients, was performed on 139 patients (96%) over a mean of 3.1 years.

Main Results:

  • LV ejection fraction (LVEF) was preserved in 97.1% of patients, with only 4 patients (2.9%) developing mild LV systolic dysfunction (LVEF 44-54%).
  • Significant improvements were observed in mitral regurgitation severity (67% improved), resting LVOT gradient (75 to 19 mm Hg), provoked LVOT gradient (101 to 33 mm Hg), and New York Heart Association class (2.9 to 1.3).

Conclusions:

  • Alcohol septal ablation for symptomatic HC results in only mild reduction of LV systolic function in a minority of patients.
  • The procedure leads to significant improvements in echocardiographic and functional parameters, supporting its role in managing HC.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K